Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In partnership with the US FDA, Alport Syndrome Foundation (ASF) is the driving force behind the ASSENT network, an international initiative to develop efficient surrogate endpoints to stimulate drug development and bring new therapies to patients with Alport syndrome (“AS”, ICD10 = Q87.81). This initiative aims to bring together analysis of datasets from all corners of the world to provide robust evidence to support surrogate endpoint use. Key stakeholders will include patients, caregivers, academics (nephrologists, biostatisticians, dataset holders), regulators, and industry partners.
Despite being first classified nearly 100 years ago, the monogenetic glomerulonephropathy, AS, remains without an on-label, regulatory-approved therapy to slow patients’ progression to kidney failure. While dialysis and transplantation remain viable options to continue life for AS patients, quality-of-life is significantly impacted on dialysis and availability of suitable transplantable donor organs remain significantly constrained globally for the foreseeable future.
Based on its biological plausibility, proteinuria, in conjunction with estimated Glomerular Filtration Rate (eGFR) and high-level genotype classification (i.e. X-Linked Male, X-Linked Female, Autosomal Recessive, Autosomal Dominant), is hypothesized to be a reasonably likely surrogate endpoint for kidney failure in AS. To prove this hypothesis to the U.S. FDA’s definition of reasonable likelihood will require an assemblage of an AS patient database larger in patient number and deeper and denser in longitudinal collection points than any single registry known to exist globally at this time.5 ASSENT seeks to assemble this unified global registry and then perform the FDA-aligned biostatistical analysis to present data-based evidence to the FDA. If ASSENT is successful in this presentation, it is predicted clinical trials for AS will become much more efficient and practical. This in turn will increase the likelihood of on-label therapies coming to market for this century-old unmet need.
ASSENT is the direct outcome of the ASF’s Research & Regulatory Workshop held in Cambridge, Massachusetts, USA in early May 2025 which included leading experts in Alport syndrome from around the U.S., United Kingdom, and Canada and included the U.S. FDA and NIH participants. Work groups were formed at that meeting, including one focused on AS data collection and analysis which evolved into ASSENT. Since May, a meeting was scheduled with the FDA on December 2nd 2025 for presentation of a formalized proposal and timeline and efforts are now progressing to optimize the impact and alignment of this meeting.
As such, ASSENT is then planned to occur through a step-wise process:
1. On December 2nd, 2025 the ASF will assemble a team of volunteer clinical, scientific, and patient experts4 to propose the ASSENT plan to the US FDA’s Center for Drug Evaluation Research’s Division of Cardiology & Nephrology on the FDA’s White Oak campus in Silver Spring, MD, USA including:
a. Providing evidence for the biological plausibility of the hypothesis.
b. Present a prioritized census of the global registries that are anticipated to take part in ASSENT.
c. Present a biostatistical plan for how the registry data will be unified and mined.
d. Propose the infrastructure and legal framework to support b. and c. above.
e. Share the framework, scope of work, and funding needs with potential bio/pharmaceutical sponsors.
f. Publication of the over-all effort and assigning a timeframe and actionable initiative end-points to determine if the hypothesis has been shown to meet reasonable likelihood or not
2. Once alignment is achieved with the FDA the ASF will lead a kick-off meeting to launch parallel tracks to forge the legal agreements to harmonize global registry datasets and the framework for bio/pharmaceutical sponsorship, participation, and access to results.
These will be updated to show the progress at the time of the World Congress of Nephrology.
